<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02719912</url>
  </required_header>
  <id_info>
    <org_study_id>CIP 01-2015</org_study_id>
    <nct_id>NCT02719912</nct_id>
  </id_info>
  <brief_title>Mitral Valve Replacement With MValve Dock and Lotus</brief_title>
  <acronym>DOCK 1</acronym>
  <official_title>Mitral Valve Replacement With the MValve Dock and A Percutaneous Transcatheter Heart Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MValve Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MValve Technologies Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the MValve mitral prosthesis in conjunction with a Lotus transcatheter
      heart valve (THV) for mitral valve replacement in subjects at high risk for conventional
      mitral valve replacement or repair surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective first in man feasibility study intended to evaluate preliminary
      safety and effectiveness of the MValve Mitral Dock with Lotus transcatheter heart valve for
      mitral valve replacement in subjects who are at high risk for surgical valve repair or
      replacement.

      The surgical technique adapts the valve-in-valve approach for mitral replacement in
      degenerated mitral prostheses to failing native mitral valves. The MValve Dock is designed to
      provide a structural platform within the mitral annulus so that the Lotus THV can be
      implanted in a secure fashion in the mitral annulus. The investigational device anchors to
      the mitral annulus commissures, sparing the native valve leaflets and sub annular apparatus.
      This study is designed to treat subjects with moderate-to-severe MR who are not deemed
      candidates for mitral valve surgery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite serious adverse cardiac events and stroke</measure>
    <time_frame>30 days</time_frame>
    <description>death, myocardial infarction, stroke, repeat surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation grade</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Valve Replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitral valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>mitral valve replacement</intervention_name>
    <description>transcatheter mitral valve replacement</description>
    <arm_group_label>Valve Replacement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic ≥3+ degenerative or functional mitral regurgitation of either ischemic or
             non-ischemic etiology based by a qualifying echocardiography obtained within 90 days
             prior to the procedure.

          -  New York Heart Association (NYHA) Functional Class III or IV.

          -  High risk for conventional open mitral valve repair or replacement surgery in the
             consideration of the site Heart Team.

          -  Left Ventricular Ejection Fraction (LVEF) is ≥30% within 30 days prior to the
             procedure.

          -  Mitral valve annular commissure to commissure (C/C) dimension between 30-35 mm by
             echocardiography.

          -  Left atrial diameter &lt;5.5 cm by echocardiography

        Exclusion Criteria:

          -  Prior mitral valve replacement or repair surgery.

          -  Prior transapical surgery.

          -  Severe aortic or tricuspid valve disease. - Severe symptomatic carotid stenosis (&gt;70%
             by ultrasound).

          -  ACC/AHA Stage D heart failure.

          -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or
             any other structural heart disease causing heart failure other than dilated
             cardiomyopathy of either ischemic or non-ischemic etiology.

          -  Infiltrative cardiomyopathies (amyloidosis, hemochromatosis, sarcoidosis).

          -  Physical evidence of right-sided congestive heart failure with echocardiographic
             evidence of moderate or severe right ventricular dysfunction.

          -  Severe mitral annular calcification.

          -  Glomerular filtration rate (GFR) &lt; 30.

          -  Hemodynamic instability defined as systolic pressure &lt; 90 mm Hg with or without
             afterload reduction, cardiogenic shock, or the need for inotropic support or
             intra-aortic balloon pump or other hemodynamic support device, or any mechanical heart
             assistance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dante Pazzenese Institute of Cardiology</name>
      <address>
        <city>Sau Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Abizaid, MD</last_name>
    </contact>
    <contact_backup>
      <email>aabizaid@uol.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Abizaid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederic Petit</last_name>
      <email>fpetit@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Didier Tchetche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bonn - Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaja Twelker, MD</last_name>
      <email>kaja.twelker@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Georg Nickenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Poznan</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maciej Lesiak, MD</last_name>
    </contact>
    <contact_backup>
      <email>maciej.lesiak@skpp.edu.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Maciej Lesiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2016</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

